CDKN2A and acral lentiginous melanoma: In addition, genetic alterations in CDK4 pathway components (CDK4, CCND1, and CDKN2A), which are particularly common in Asians, have been associated with innate resistance to PD-1 blockade in patients with acral melanoma (93).